Patent · US Active

Formulations of tegavivint

US11964054B2 · kind B2 · utility

0Cited by
0References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 6, 2023
Grant dateApr 23, 2024
Priority date—
Expiry dateFeb 6, 2043

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/26
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.